Chang David D 4
4 · Allogene Therapeutics, Inc. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Allogene (ALLO) CEO David Chang Sells 47,763 Shares
What Happened
David D. Chang, President, CEO and a director of Allogene Therapeutics (ALLO), sold 47,763 shares of Allogene common stock on March 16, 2026 at $2.47 per share for proceeds of $117,975. The filing reports this was a sale (S) and is characterized as a sell-to-cover to satisfy tax withholding on vested restricted stock units, not a discretionary open-market divestiture.
Key Details
- Transaction date: 2026-03-16; Sale price: $2.47 per share; Total proceeds: $117,975.
- Filing date / accession: Form 4 filed 2026-03-18 (timely filed within SEC rules).
- Shares owned after the transaction: Not specified in the filing.
- Notable footnotes:
- F1: Sale mandated to cover tax withholding on RSU vesting (sell-to-cover), not a discretionary trade.
- F2: Filing notes Chang acquired 12,500 shares on Mar 15, 2026 via the employee stock purchase program.
- F3–F5: Additional shares are held in various trusts (RTC 2019, JEC 2019, Chang 2006 Family Trust).
Context
This was a routine sell-to-cover transaction to satisfy tax obligations on vested awards and does not necessarily signal the insider’s view on the company’s prospects. Purchases generally provide stronger evidence of insider confidence; this filing documents a tax-related sale.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-16$2.47/sh−47,763$117,975→ 5,150,599 total
- 856,044(indirect: See footnote)
Common Stock
[F3] - 856,044(indirect: See footnote)
Common Stock
[F4] - 1,201,108(indirect: See footnote)
Common Stock
[F5]
Footnotes (5)
- [F1]1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
- [F3]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F5]Securities held in the name of the Chang 2006 Family Trust